CurrentUnitedHealthcarePolicy N/A

Somavert (pegvisomant) prior authorization and medical necessity

Defines UnitedHealthcare prior authorization and medical necessity criteria for Somavert (pegvisomant) for treatment of acromegaly, including initial authorization and reauthorization rules that affect prescribers and pharmacy benefit management.

Policy Summary

PayerUnitedHealthcare

PolicySomavert (pegvisomant) prior authorization and medical necessity

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateOct 1, 2025

Next Review DateJul 1, 2025

Key ActionSubmit prior authorization with documentation confirming acromegaly diagnosis and evidence of inadequate response/intolerance to prior therapies or current Somavert use.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period

SSA failureinitial auth requirement

Current therapy OKalternative pathway

Clinical responsereauthorization

State mandatesadministrative note

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial Authorization

Covered when ALL of the following are met (pathway 1) OR when pathway 2 applies:

Diagnostic confirmation: Diagnosis of acromegaly confirmed by one of: (i) Serum GH > 1 ng/mL after a 2-hour oral glucose tolerance test (OGTT) at time of diagnosis OR (ii) Elevated serum IGF-1 above the age- and gender-adjusted normal range at time of diagnosis.GH > 1 ng/mL or elevated IGF-1

Prior therapy requirement (one of): Either (i) inadequate response to surgery, radiation therapy, or dopamine agonist therapy OR (ii) not a candidate for surgery, radiation therapy, or dopamine agonist therapy.N/A

SSA requirement: Inadequate response, intolerance, or contraindication to a long-acting somatostatin analog (e.g., octreotide LAR, lanreotide depot).N/A

Alternative initial pathway: Patient is currently receiving Somavert (pegvisomant) therapy for acromegaly.N/A

Authorization will be issued for 12 months.

Reauthorization

Covered when the following is documented:

Clinical response: Documentation of positive clinical response to Somavert therapy (example: normalized or improved serum IGF-1 level).Normalized or improved IGF-1 as documented

Authorization will be issued for 12 months.

Coverage decisions for Somavert (pegvisomant) may be affected by state mandates, the member’s specific benefit plan coverage, other UnitedHealthcare medical policies, and utilization management programs. UnitedHealthcare may use automated approval or re-approval processes and may approve initial or reauthorization requests based solely on prior claim/medication history, diagnosis codes, and/or claim logic depending on the program or therapeutic class. Supply limits may also apply.

The policy document does not list any explicit Not Medically Necessary (NMN) statements for Somavert. Additional clinical rules note that UnitedHealthcare may nonetheless apply program- or class-specific automated approval logic, prior claim history, diagnosis codes, or claim logic in determining coverage.

Coding and Diagnostic Thresholds

Referenced coding/claim logicmixed

No codes listed

GH after OGTT diagnostic threshold

GH threshold after 2-hour OGTT> 1 ng/mL

Test timingMeasured after a 2-hour oral glucose tolerance test (OGTT) at time of diagnosis

Use in diagnostic pathwayOne of the diagnostic criteria required for initial Somavert authorization

Prescriber and Pharmacy Actions / Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Somavert (pegvisomant). Requests will be reviewed against the clinical criteria for approval (diagnosis confirmation, prior therapies, and response to therapy). Authorization, when approved, will be issued for 12 months.

Affected drug: Somavert (pegvisomant)
Authorization period: 12 months

Step Therapy

Step Therapy: Somatostatin Analog Requirement

Step therapy requires documentation of inadequate response, intolerance, or contraindication to a long-acting somatostatin analog (SSA) prior to approval of Somavert. Accepted long-acting SSAs include examples such as Sandostatin LAR (octreotide) and Somatuline Depot (lanreotide).

Step therapy requirement: inadequate response, intolerance, or contraindication to a long-acting SSA
Examples: Sandostatin LAR (octreotide); Somatuline Depot (lanreotide)

Key Definitions and Diagnostic Criteria

Diagnostic criteria for acromegaly

OGTT GH criterion> 1 ng/mL after a 2-hour oral glucose tolerance test (OGTT)

IGF-1 criterionElevated serum IGF‑1 above age- and gender‑adjusted normal range as provided by the physician's lab

Role in authorizationRequired diagnostic confirmation for initial Somavert approval (one of the listed criteria)

Long-acting somatostatin analog (SSA) failure

Definition of SSA failureInadequate response, intolerance, or contraindication to a long-acting somatostatin analog

Examples of long‑acting SSAsSandostatin LAR (octreotide), Somatuline Depot (lanreotide)

Background and Clinical Context

Pegvisomant (Somavert) is referenced in clinical background as a targeted therapy for acromegaly; use and authorization are governed by the clinical criteria and additional program rules in this policy. UnitedHealthcare’s additional clinical rules emphasize that prior treatment history and claim/medication records may influence initial and reauthorization decisions, and supply limits may be enforced.

Documentation Required

Required Clinical Documentation

Provide the following documentation with the initial authorization request: confirmation of acromegaly diagnosis (OGTT GH > 1 ng/mL or elevated age- and sex-adjusted IGF-1), details of prior therapies (surgery, radiation, dopamine agonists) and evidence of inadequate response to those therapies if applicable, and documentation of inadequate response, intolerance, or contraindication to a long-acting SSA. For reauthorization, submit documentation of positive clinical response to Somavert (for example, normalized serum IGF-1).

Diagnosis confirmation: OGTT with nadir GH > 1 ng/mL OR elevated serum IGF-1 above age/gender-adjusted range
Prior therapy details: surgery, radiation, or dopamine agonist therapy and documentation of inadequate response when claimed
SSA documentation: evidence of inadequate response, intolerance, or contraindication to a long-acting somatostatin analog
Reauthorization: evidence of clinical benefit (e.g., normalized IGF-1)